Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10350238 | 0.80 | ALDH1A1 (0.60) | HPGDTSHRCYP1A2CYP3A4MAPT | |
| SCHEMBL12517400 | 0.80 | ALDH1A1 (0.60) | HPGDTSHRCYP1A2CYP3A4MAPT | |
| SCHEMBL5459285 | 0.79 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DHPGD | |
| SCHEMBL9774931 | 0.79 | RAB9A (0.57) | HPGDTSHRCYP1A2CYP3A4MAPT | |
| SCHEMBL5457259 | 0.76 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DHPGD | |
| SCHEMBL5632239 | 0.75 | SRD5A2 (0.58) | PDE4APDE4BPDE4CPDE4DHPGD | |
| SCHEMBL12319180 | 0.74 | TDP1 (0.67) | HPGDTSHRCYP1A2CYP3A4MAPT | |
| SCHEMBL1160078 | 0.74 | TDP1 (0.67) | HPGDTSHRCYP1A2CYP3A4MAPT | |
| SCHEMBL2222829 | 0.74 | PKM (0.54) | HPGDTSHRCYP1A2CYP3A4MAPT | |
| SCHEMBL10733109 | 0.74 | ALDH1A1 (0.62) | HPGDTSHRCYP1A2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1565472-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | PDE4A 7/4885PDE4B 8/4885PDE4C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.